CBMG shows strong data in early CART trials

Chinese biotech Cellular Biomedicine Group (CBMG) shed some light on its early stage cancer immunotherapy program during an investor day in New York on 25 March. The company presented data from Phase I trials in a small number of patients that were treated with their chimeric antigen receptor-T cell (CART) technology. The CART space has been one of the hottest areas in oncology over the last year as big players like Novartis and smaller players like Cellectis have moved their therapies forward and shown impressive results in clinical trials; most recently, Cellectis increased the amount it plans to raise in an IPO by 70% to $197m based on the strength of its CART programs. CBMG is hoping to join the frenzy. The Chinese biotech reported that nine patients with relapsed or chemo-refractory B-cell acute lymphocytic leukemia received its CAR-CD19 T-cell therapy. Two of nine patients, or 22.2%, showed a complete response, while four of nine patients, or 44.4%, achieved a partial response – resulting in a 66.7% overall response rate (ORR). Meanwhile, seven patients with advanced diffuse large B-cell lymphoma were given the company's CAR-CD20 T-cell therapy. One of the two patients in the trial with no bulky tumors achieved a 14-month durable and ongoing complete remission and another achieved a 6-month tumor regression resulting in an ORR of 100%. Three of four patients with evaluable bulky tumor burden achieved three to six month tumor regression for an ORR 75%. While the results are encouraging, the data is very early and the number of patients in the trial is too small to be translatable to later-stages.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Anticancer

GSK’s Blenrep US Setback Could Go From Bad To Worse

 

With a US approval any time soon now looking unlikely, analysts are revising Blenrep’s peak sales guidance downwards.

Boehringer Ingelheim Expects Two Key Approvals In Second Half Of 2025

 

The privately held German pharma firm is hoping to bring a new generation of pulmonary fibrosis and cancer drugs to market but their commercial success is not yet a certainty.

Dispatch Uses ‘Flare’ To Send CAR-Ts To Solid Tumors

 

With $216m in initial funding, the newly launched company is aiming to develop a cell therapy-based universal immuno-oncology option for solid tumor indications.

After Gilead Deal, Hookipa Hangs Up Its Hat

 
• By 

The Austrian firm is delisting from the NASDAQ and closing down.

More from Therapy Areas

Memo Therapeutics Plans BK Virus Therapy Phase III Despite Trial Miss

 
• By 

Pointing to data that show a benefit in reducing viral load and the histological signs of the infection, Memo says its drug, potravitug, could become the first therapy to treat BK polyomavirus in kidney transplant recipients.

Viking Rapidly Advancing Oral And Injectable VK2735 For Obesity

 
• By 

In its Q2 update, Viking reported that Phase III trials of subcutaneous VK2735 are under way, and that it expects Phase II data for an oral formulation before year’s end.

Leo Looks To Grow In US After Hand Eczema Cream Approval

 
• By 

The Danish medical dermatology specialist doubles boosts its sales force ahead of the launch of Anzupgo.